PP
ACHV icon

Paloma Partners’s Achieve Life Sciences ACHV Stock Holding History

Paloma Partners’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-29
Closed -$234K – 979
2014
Q2 		$234K Buy
+29
New +$356K 0.01% 897

Other funds holding ACHV

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

Paloma Partners's ACHV Position: Q3 2014 in Review

Paloma Partners sold out of Achieve Life Sciences (ACHV) in Q3 2014, closing a stake of 29 shares — an estimated $234K sold.

Paloma Partners first reported a position in ACHV in Q2 2014 and held it in 1 quarter. The position peaked at $234K in Q2 2014. 52 funds tracked by Wall St. Rank hold ACHV as of Q3 2014.

  • Paloma Partners reported no remaining Achieve Life Sciences position as of Q3 2014 after selling out during the quarter.
  • Paloma Partners sold 29 Achieve Life Sciences shares in Q3 2014, an estimated $234K.
  • Paloma Partners first reported a position in Achieve Life Sciences in Q2 2014 and held it in 1 quarter.
  • Paloma Partners's Achieve Life Sciences position peaked at $234K in Q2 2014.
  • 52 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q3 2014.

Based on Paloma Partners's 13F filing for Q3 2014, filed 14 Nov 2014.